The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...
CNN on MSN8d
A little-known Chinese company made a drug that beat the world’s biggest-selling medicineChina’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...
Varda Space Industries achieved the first successful commercial space reentry in Australia, a milestone for the industry. Varda's co-founder and president, Delian Asparouhov, joins Josh Lipton on ...
Pharmalittle: We’re reading about lower Wegovy prices, a dispute over Merck’s Keytruda, and more
Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...
Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback